Abstract:Objective: To test whether cerebrospinal fluid (CSF) α-synuclein is altered in Alzheimer’s disease (AD) and different AD pathophysiological profiles based on “ATN” classifications and whether it associated with other AD biomarkers, cognitive decline and imaging evidence of neurodegeneration. Background: More than 50% sporadic AD patients exhibit accumulation of α-synuclein in their brains. CSF α-synuclein could be a potential biomarker of AD. Design/Methods: This prospective case-control study included 385 subjects: 109 cognitively healthy controls, 117 patients with stable mild cognitive impairment (sMCI), 68 patients with progressive mild cognitive impairment (pMCI) and 91 patients with AD dementia from the Alzheimer’s disease Neuroimaging Initiative. The study dates were September 2005, to December 2011. Associations were investigated between CSF α-synuclein and diagnosis, Aβ/tau pathologic features, cognition, brain structure and metabolism. Results: CSF α-synuclein concentration was significantly higher in the AD and pMCI groups compared with the cognitively normal group (P Conclusions: CSF α-synuclein is associated with AD diagnosis and with CSF tau levels, cognition and imaging evidence of neurodegeneration of the disease. This finding implies usefulness for CSF α-synuclein as a potential biomarker for AD. Study Supported by: Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI)(National Institutes of Health Grant U01 AG024904) and DOD ADNI(Department of Defense award number W81XWH-12-2-0012). ADNIis funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; Euro Immun; and F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare;; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research u0026 Development, LLC.; Johnson u0026 Johnson Pharmaceutical Research u0026 Development LLC.; Medpace, Inc.; MerckC Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuroimaging at the University of Southern California Disclosure: Dr. Li has nothing to disclose. Dr. Yu has nothing to disclose. Dr. Tan has nothing to disclose.

Contactin proteins in cerebrospinal fluid show different alterations in dementias

Identification of Candidate Biomarkers of Alzheimer's Disease Via Multiplex Cerebrospinal Fluid and Serum Proteomics.

Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders.

Global Protein Differential Expression Profiling of Cerebrospinal Fluid Samples Pooled from Chinese Sporadic CJD and non-CJD Patients

Targeted proteomic profiling in cerebrospinal fluid and plasma identifies biomarkers for Alzheimer’s disease

Correlation between alterations in resting-state functional connectivity of brain network and cerebrospinal fluid pathological markers in patients with Alzheimer's disease

Can Small Molecules Provide Clues on Disease Progression in Cerebrospinal Fluid from Mild Cognitive Impairment and Alzheimer’s Disease Patients?

Exploratory Assessment of Proteomic Network Changes in Cerebrospinal Fluid of Mild Cognitive Impairment Patients: A Pilot Study

Increased levels of neuronal thread protein in cerebrospinal fluid of patients with Alzheimer's disease

Association between plasma CTRPs with cognitive impairment and neurodegeneration of Alzheimer's disease

Difference of Cerebrospinal Fluid Biomarkers and Neuropsychiatric Symptoms Profiles among Normal Cognition, Mild Cognitive Impairment, and Dementia Patient

Cerebrospinal fluid biomarker panel for synaptic dysfunction in a broad spectrum of neurodegenerative diseases

Comparison of Commonly Measured Plasma and Cerebrospinal Fluid Proteins and Their Significance for the Characterization of Cognitive Impairment Status

Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer's disease and frontotemporal dementia

Dissection of synaptic pathways through the CSF biomarkers for predicting Alzheimer disease

CSF synaptic protein concentrations are raised in those with atypical Alzheimer’s disease but not frontotemporal dementia

CSF neurogranin levels as a biomarker in Alzheimer's disease and frontotemporal lobar degeneration: a cross-sectional analysis

Cerebrospinal fluid α-synuclein as a potential biomarker for Alzheimer’s disease (P4.174)

[Diagnostic value of AD7C-NTP for patients with mild cognitive impairment due to Alzheimer's disease].

Genome-wide Association Study of Cerebrospinal Fluid Neurofilament Light Levels in Non-Demented Elders.

Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer’s disease